Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ADMA Biologics Inc (ADMA : NSDQ)
 
 • Company Description   
ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.

Number of Employees: 647

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.72 Daily Weekly Monthly
20 Day Moving Average: 3,163,211 shares
Shares Outstanding: 223.99 (millions)
Market Capitalization: $2,177.13 (millions)
Beta: 0.70
52 Week High: $20.46
52 Week Low: $7.21
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.04% 0.99%
12 Week 7.05% 5.01%
Year To Date -46.71% -52.76%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
465 STATE ROUTE 17
-
RAMSEY,NJ 07446
USA
ph: 201-478-5552
fax: 201-478-5553
adma@argotpartners.com http://www.admabiologics.com
 
 • General Corporate Information   
Officers
Adam S. Grossman - President; Chief Executive Officer and Director
Steven A. Elms - Chairman
Jerrold B. Grossman - Vice Chairman
Brad Tade - Chief Financial Officer
Alison Finger - Director

Peer Information
ADMA Biologics Inc (CORR.)
ADMA Biologics Inc (RSPI)
ADMA Biologics Inc (CGXP)
ADMA Biologics Inc (BGEN)
ADMA Biologics Inc (GTBP)
ADMA Biologics Inc (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 000899104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/04/26
Share - Related Items
Shares Outstanding: 223.99
Most Recent Split Date: (:1)
Beta: 0.70
Market Capitalization: $2,177.13 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.22 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.78 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/04/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 12.52
Trailing 12 Months: 13.69
PEG Ratio: -
Price Ratios
Price/Book: 5.37
Price/Cash Flow: 14.86
Price / Sales: 4.25
EPS Growth
vs. Year Ago Period: 6.67%
vs. Previous Quarter: -15.79%
Sales Growth
vs. Year Ago Period: 1.98%
vs. Previous Quarter: 8.65%
ROE
09/30/26 - -
06/30/26 - 40.17
03/31/26 - 39.98
ROA
09/30/26 - -
06/30/26 - 26.97
03/31/26 - 28.08
Current Ratio
09/30/26 - -
06/30/26 - 6.97
03/31/26 - 6.95
Quick Ratio
09/30/26 - -
06/30/26 - 3.81
03/31/26 - 3.93
Operating Margin
09/30/26 - -
06/30/26 - 33.47
03/31/26 - 33.27
Net Margin
09/30/26 - -
06/30/26 - 32.98
03/31/26 - 32.43
Pre-Tax Margin
09/30/26 - -
06/30/26 - 42.26
03/31/26 - 40.47
Book Value
09/30/26 - -
06/30/26 - 1.81
03/31/26 - 1.68
Inventory Turnover
09/30/26 - -
06/30/26 - 0.84
03/31/26 - 0.97
Debt-to-Equity
09/30/26 - -
06/30/26 - 0.49
03/31/26 - 0.51
Debt-to-Capital
09/30/26 - -
06/30/26 - 32.76
03/31/26 - 33.87
 

Powered by Zacks Investment Research ©